Reply to: Comment on “Serious infections among a large cohort of subjects with systemically treated psoriasis” - 19/04/18
Doi : 10.1016/j.jaad.2017.12.017
Allison S. Dobry, MD a, Charles P. Quesenberry, PhD b, Maryam M. Asgari, MD, MPH b, c, d, ⁎ 
a Department of Medicine, Cambridge Health Alliance, Cambridge, Massachusetts
b Division of Research, Kaiser Permanente Northern California, Oakland, California
c Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
d Department of Population Medicine, Harvard Medical School, Boston, Massachusetts
∗Correspondence to: Maryam M. Asgari, MD, MPH, Department of Dermatology. Massachusetts General Hospital, 50 Staniford St, Ste 270, Boston, MA 02114Department of Dermatology. Massachusetts General Hospital50 Staniford StSte 270BostonMA02114
Le texte complet de cet article est disponible en PDF.
| Funding sources: Supported by Pfizer Inc and the National Institute of Arthritis, Musculoskeletal and Skin Diseases (K24 AR069760 to Dr Asgari). |
|
| Conflicts of interest: In addition to research support from Pfizer Inc, Drs Asgari and Quesenberry have received research support from Valeant Pharmaceuticals. Dr Dobry has no conflicts of interest to report. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 5
P. e115 - mai 2018 Retour au numéro
Article précédent
- Comment on “Serious infections among a large cohort of subjects with systemically treated psoriasis”
- David L. Arnold, Steven R. Feldman
- Comment on “The role of the ugly duckling sign in patient education”
- Stuart M. Goldsmith
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?